N-(3-Cyano-6-oxo-4,5,6,7-tetrahydro-benzo[b]thiophen-2-yl)-2-ethyl-butyramide | 675572-71-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(3-Cyano-6-oxo-4,5,6,7-tetrahydro-benzo[b]thiophen-2-yl)-2-ethyl-butyramide
• 英文别名: N-(3-Cyano-6-oxo-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-ethylbutanamide；N-(3-cyano-6-oxo-5,7-dihydro-4H-1-benzothiophen-2-yl)-2-ethylbutanamide
• CAS: 675572-71-1
• 化学式: C₁₅H₁₈N₂O₂S
• 分子量: 290.386
• InChiKey: LAUGVTATJUTWBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  98.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(3-Cyano-6-oxo-4,5,6,7-tetrahydro-benzo[b]thiophen-2-yl)-2-ethyl-butyramide 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 生成 N-{3-Cyano-6-[(2,4-dichloro-benzyl)-methyl-amino]-4,5,6,7-tetrahydro-benzo[b]thiophen-2-yl}-2-ethyl-butyramide
  参考文献：
  名称：

  Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor

  摘要：

  A novel class of antagonists of the human glucagon receptor (bGCGR) has been discovered. Systematic modification of the lead compound identified substituents that were essential for activity and those that were amenable to further optimization. This SAR exploration resulted in the synthesis of 13, which exhibited good potency as an hGCGR functional antagonist (IC50 = 34 nM) and moderate bioavailability (36% in mice). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.003
• 作为产物：
  描述：

  N-(3'-cyanospiro[1,3-dioxolane-2,6'-5,7-dihydro-4H-1-benzothiophene]-2'-yl)-2-ethylbutanamide 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 生成 N-(3-Cyano-6-oxo-4,5,6,7-tetrahydro-benzo[b]thiophen-2-yl)-2-ethyl-butyramide
  参考文献：
  名称：

  Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor

  摘要：

  A novel class of antagonists of the human glucagon receptor (bGCGR) has been discovered. Systematic modification of the lead compound identified substituents that were essential for activity and those that were amenable to further optimization. This SAR exploration resulted in the synthesis of 13, which exhibited good potency as an hGCGR functional antagonist (IC50 = 34 nM) and moderate bioavailability (36% in mice). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.003

文献信息

• Substituted bicyclic thiophene derivatives, compositions containing such compounds and methods of use
  申请人：Duffy Joseph

  公开号：US20050239865A1

  公开（公告）日：2005-10-27

  The present invention addresses substituted thiophene derivatives, as well as compositions containing such compounds and methods of treatment. The compounds in the present invention are glucagon antagonists. The compounds block the action of glucagon at its receptor and thereby decrease the levels of plasma glucose providing a treatment of diabetes.

  本发明涉及取代噻吩衍生物，以及含有这些化合物的组合物和治疗方法。本发明中的化合物是胰高血糖素拮抗剂。这些化合物可以阻断胰高血糖素在其受体上的作用，从而降低血浆葡萄糖水平，提供糖尿病的治疗。
• Substituted bicylic thiophene derivatives, compositions containing such compounds and methods of use
  申请人：Merck & Co., Inc.

  公开号：US07273876B2

  公开（公告）日：2007-09-25

  The present invention addresses substituted thiophene derivatives, as well as compositions containing such compounds and methods of treatment. The compounds in the present invention are glucagon antagonists. The compounds block the action of glucagon at its receptor and thereby decrease the levels of plasma glucose providing a treatment of diabetes.

  本发明涉及取代噻吩衍生物，以及含有这些化合物的组合物和治疗方法。本发明中的化合物是葡萄糖高原激素拮抗剂。这些化合物可以阻止葡萄糖高原激素在其受体上的作用，从而降低血浆葡萄糖水平，提供糖尿病治疗。
• SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSTIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
  申请人：Merck & Co., Inc.

  公开号：EP1549655B1

  公开（公告）日：2009-01-21
• US7273876B2
  申请人：——

  公开号：US7273876B2

  公开（公告）日：2007-09-25
• Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor
  作者：Joseph L. Duffy、Brian A. Kirk、Zenon Konteatis、Elizabeth L. Campbell、Rui Liang、Edward J. Brady、Mari Rios Candelore、Victor D.H. Ding、Guoqiang Jiang、Frank Liu、Sajjad A. Qureshi、Richard Saperstein、Deborah Szalkowski、Sharon Tong、Lauri M. Tota、Dan Xie、Xiaodong Yang、Peter Zafian、Song Zheng、Kevin T. Chapman、Bei B. Zhang、James R. Tata

  DOI：10.1016/j.bmcl.2005.01.003

  日期：2005.3

  A novel class of antagonists of the human glucagon receptor (bGCGR) has been discovered. Systematic modification of the lead compound identified substituents that were essential for activity and those that were amenable to further optimization. This SAR exploration resulted in the synthesis of 13, which exhibited good potency as an hGCGR functional antagonist (IC50 = 34 nM) and moderate bioavailability (36% in mice). (c) 2005 Elsevier Ltd. All rights reserved.